Patents by Inventor Darren DiSalvo
Darren DiSalvo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8940893Abstract: The present invention encompasses compounds of the formula (I) wherein the groups X and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.Type: GrantFiled: March 14, 2014Date of Patent: January 27, 2015Assignee: Boehringer Ingelheim International GmbHInventors: Todd Bosanac, Darren Disalvo, Joshua Courtney Horan, Shuang Liang, Renee M. Zindell
-
Patent number: 8895750Abstract: The present invention encompasses compounds of the formula (I) wherein the groups ring A and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.Type: GrantFiled: March 13, 2014Date of Patent: November 25, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Todd Bosanac, Michael J. Burke, Darren Disalvo, Wang Mao, John Westbrook
-
Publication number: 20140275012Abstract: The present invention encompasses compounds of the formula (I) wherein the groups ring A and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Todd BOSANAC, Michael J. BURKE, Darren DISALVO, Wang MAO, John WESTBROOK
-
Publication number: 20140275014Abstract: The present invention encompasses compounds of the formula (I) wherein the groups X and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Todd BOSANAC, Darren DISALVO, Joshua Courtney HORAN, Shuang LIANG, Renee M. ZINDELL
-
Patent number: 8658637Abstract: Compounds of Formula (IA) wherein R1, R2, R3, A, B, C, D, E, G, X, Y, and Z are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.Type: GrantFiled: November 29, 2007Date of Patent: February 25, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Daniel Kuzmich, Darren DiSalvo, Hossein Razavi, Michael Jason Burke
-
Patent number: 8546442Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.Type: GrantFiled: December 16, 2011Date of Patent: October 1, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Rajashekhar Betageri, Brian Nicholas Cook, Darren DiSalvo, Christian Harcken, Daniel Kuzmich, Pingrong Liu, John Lord, Can Mao, Hossein Razavi
-
Publication number: 20120322790Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.Type: ApplicationFiled: December 16, 2011Publication date: December 20, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Rajashekhar BETAGERI, Brian Nicholas COOK, Darren DiSALVO, Christian HARCKEN, Daniel KUZMICH, Pingrong LIU, John LORD, Can MAO, Hossein RAZAVI
-
Publication number: 20120136158Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.Type: ApplicationFiled: February 8, 2012Publication date: May 31, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Brian Nicholas COOK, Darren DiSALVO, Daniel Robert FANDRICK, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Jonathan Timothy REEVES, Jinhua J. SONG, Alan David SWINAMER, Zhulin TAN
-
Publication number: 20120035370Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.Type: ApplicationFiled: October 14, 2011Publication date: February 9, 2012Applicant: Boehringer Ingelheim International GmbHInventors: Brian Nicholas COOK, Darren DiSALVO, Daniel Robert FANDRICK, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Jonathan Timothy REEVES, Jinhua J. SONG, Alan David SWINAMER, Zhulin TAN
-
Patent number: 8008327Abstract: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: April 23, 2009Date of Patent: August 30, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Darren DiSalvo, Daniel Kuzmich, Can Mao, Hossein Razavi, Christopher Ronald Sarko, Alan David Swinamer, David Smith Thomson, Qiang Zhang
-
Publication number: 20110086846Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.Type: ApplicationFiled: December 16, 2010Publication date: April 14, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Brian Nicholas COOK, Darren DiSALVO, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Alan David SWINAMER
-
Publication number: 20110034512Abstract: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: April 23, 2009Publication date: February 10, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Darren Disalvo, Daniel Kuzmich, Can Mao, Hossein Razavi, Christopher Sarko, Alan David Swinamer, David Smith Thomson, Qiang Zhang
-
Patent number: 7879873Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.Type: GrantFiled: September 22, 2009Date of Patent: February 1, 2011Assignee: Boehringer Ingelheim International GmbHInventors: Brian Nicholas Cook, Darren DiSalvo, Daniel Robert Fandrick, Christian Harcken, Daniel Kuzmich, Thomas Wai-Ho Lee, Pingrong Liu, John Lord, Can Mao, Jochen Neu, Brian Christopher Raudenbush, Hossein Razavi, Jonathan Timothy Reeves, Jinhua J. Song, Alan David Swinamer, Zhulin Tan
-
Publication number: 20100197678Abstract: Compounds of Formula (IA) wherein R1, R2, R3, A, B, C, D, E, G, X, Y, and Z are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.Type: ApplicationFiled: November 29, 2007Publication date: August 5, 2010Applicant: Boehringer Ingelheim International GmbHInventors: Daniel Kuzmich, Darren DiSalvo, Hossein Razavi, Michael Jason Burke
-
Patent number: 7741361Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.Type: GrantFiled: December 16, 2005Date of Patent: June 22, 2010Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Daniel Kuzmich, Darren DiSalvo, John Robinson Regan, David S. Thomson
-
Publication number: 20100093724Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.Type: ApplicationFiled: September 22, 2009Publication date: April 15, 2010Applicant: Boehringer Ingelheim International GmbHInventors: Brian Nicholas COOK, Darren DiSALVO, Daniel Robert FANDRICK, Christian HARCKEN, Daniel KUZMICH, Thomas Wai-Ho LEE, Pingrong LIU, John LORD, Can MAO, Jochen NEU, Brian Christopher RAUDENBUSH, Hossein RAZAVI, Jonathan Timothy REEVES, Jinhua J. SONG, Alan David SWINAMER, Zhulin TAN
-
Publication number: 20100048950Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, X, R7, and R8 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.Type: ApplicationFiled: April 9, 2008Publication date: February 25, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Daniel Kuzmich, Darren Disalvo, John Robinson Regan
-
Patent number: 7635711Abstract: Compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.Type: GrantFiled: December 16, 2005Date of Patent: December 22, 2009Assignee: Boehringer-Ingelheim Pharmaceuticals, Inc.Inventors: Daniel Kuzmich, Darren DiSalvo, John Robinson Regan, David S. Thomson, Rajashekhar Betageri, Jennifer A. Kowalski
-
Patent number: 7550473Abstract: Disclosed are novel compounds of formula (I): wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: September 3, 2004Date of Patent: June 23, 2009Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Mario G. Cardozo, Derek Cogan, Charles Lawrence Cywin, George Dahmann, Darren DiSalvo, John David Ginn, Anthony S. Prokopowicz, III, Denice M. Spero, Erick Richard Roush Young
-
Publication number: 20080312185Abstract: Disclosed are methods of treating cancer by administration of compounds according to formula (I): wherein the variables R1, R2, R3 and Z are described herein.Type: ApplicationFiled: August 14, 2008Publication date: December 18, 2008Inventors: Zhidong Chen, Pier Francesco Cirillo, Darren DiSalvo, Weimin Liu, Daniel Richard Marshall, Lifen Wu, Erick Richard Roush Young